Abstract
Direct-acting oral anticoagulants (DOACs) are licensed for the
prevention of thromboembolism in non-valvular atrial fibrillation
amongst other indications. Prescribers use information derived from the
summary of product characteristics which is based on the key trials
supporting the DOAC’s market authorisation. However, prescribers may be
aware of the limitations of these trials regarding underrepresentation
of patient populations commonly encountered in clinical practice and how
this may adversely impact them. This review highlights the gaps in the
licensing evidence using 3 clinical vignettes that explore prescribing
challenges in the elderly, obese and female patients.